Your browser doesn't support javascript.
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management.
Russano, Marco; Citarella, Fabrizio; Napolitano, Andrea; Dell'Aquila, Emanuela; Cortellini, Alessio; Pantano, Francesco; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele.
  • Russano M; Department of Medical Oncology, University Campus Bio-Medico , Rome, Italy.
  • Citarella F; Department of Medical Oncology, University Campus Bio-Medico , Rome, Italy.
  • Napolitano A; Department of Medical Oncology, University Campus Bio-Medico , Rome, Italy.
  • Dell'Aquila E; Department of Medical Oncology, University Campus Bio-Medico , Rome, Italy.
  • Cortellini A; Department of Medical Oncology, St. Salvatore Hospital , L'Aquila, Italy.
  • Pantano F; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila, Italy.
  • Vincenzi B; Department of Medical Oncology, University Campus Bio-Medico , Rome, Italy.
  • Tonini G; Department of Medical Oncology, University Campus Bio-Medico , Rome, Italy.
  • Santini D; Department of Medical Oncology, University Campus Bio-Medico , Rome, Italy.
Expert Opin Biol Ther ; 20(9): 959-964, 2020 09.
Article in English | MEDLINE | ID: covidwho-615438
ABSTRACT

INTRODUCTION:

The COVID-19 pandemic occurred amid the cancer immunotherapy revolution. Immune checkpoint inhibitors (ICIs) have become the standard of care for several solid cancers and are associated with peculiar toxicities, including pneumonitis which has similar features to COVID-19 pneumonia. AREAS COVERED We summarize the main hallmarks of lung injury induced by ICIs and severe acute respiratory syndrome coronavirus 2 and discuss the critical aspects for differential diagnosis and management. Symptoms and radiological findings are often similar; conversely, treatments are quite different. Furthermore, we focus on potential interactions generating hypotheses that need confirmatory studies. EXPERT OPINION All cancer patients treated with immunotherapy should receive screening for SARS-CoV-2. This would improve the diagnosis and management of pneumonia and guide therapeutic choices. Furthermore, clinicians could estimate the risk/benefit of continuing ICI treatment in COVID-19 positive patients. Temporary withdrawal of the immunotherapy treatment pending resolution of viral infection may be a reasonable option in long-responders patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Immunotherapy / Neoplasms Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Expert Opin Biol Ther Journal subject: Biology / Therapeutics Year: 2020 Document Type: Article Affiliation country: 14712598.2020.1789097

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Immunotherapy / Neoplasms Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Expert Opin Biol Ther Journal subject: Biology / Therapeutics Year: 2020 Document Type: Article Affiliation country: 14712598.2020.1789097